This report analyzes the US market for Multiple Myeloma Therapeutics in Millions of US$. The market for multiple myeloma therapeutics is analyzed by the following Drugs: Thalomid, Revlimid, Velcade, and Others. The market for multiple myeloma therapeutics is also analyzed by the Lines of Treatment - Induction Therapy for SCT Candidates, Induction Therapy for Non-SCT Candidates, and Therapy for Relapsed or Refractory Myeloma. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 98 companies including many key and niche players such as Amgen Inc., Avalon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Kosan Biosciences, Inc., Celgene Corporation, F. Hoffmann-La Roche Ltd, Genentech, Inc., Genta Incorporated, Millennium Pharmaceuticals, Ortho Biotech Products, LP, Seattle Genetics, and Ziopharm Oncology, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Total Companies Profiled:98 (including Divisions/Subsidiaries - 104) Region/Country Players The United States 70 Canada 2 Japan 4 Europe 16 France 1 Germany 4 The United Kingdom 3 Italy 1 Spain 1 Rest of Europe 6 Asia-Pacific (Excluding Japan) 10 Middle East 2